Drawing for IT-DIAB

USPTO serial 87317376

IT-DIAB

Reviewed by CopyMark Law Group

Reg. 5410374Status 710
Filing date
Status date
Registration date
Feb 27, 2018
Examiner
MURRAY, GEORGE WILLIAM
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with IT-DIAB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Brooks R. Bruneau

BROOKS R. BRUNEAU FISHERBROYLES, LLP100 OVERLOOK CENTERSECOND FLOORPRINCETON, NJ 08540

Goods and services

ClassDescriptionStatusFirst use
001Active principles, namely, active chemical ingredients used in manufacturing pharmaceuticals for treating type II diabetes, prediabetes and their acute or chronic complicationsSECTION 8 - CANCELLED—
005Pharmaceutical preparations and substances, preparations for medical use, for the preventive and curative treatment of type II diabetes, of prediabetes and their acute or chronic complications; Preparations, products and devices for medical use, in particular, diagnostic biomarkers and cellular models for the in vivo, ex vivo or in vitro diagnosis of type II diabetes, of prediabetes and their associated acute or chronic complications; Preparations, products and devices, in particular, diagnostic biomarkers and cellular models for the medical follow-up of patients at risk or of patients suffering from type II diabetes, prediabetes and their associated acute or chronic complications; Preparations, products and devices in particular diagnostic biomarkers and cellular models for the selection and assessment of drugs and their compounds for their preventive and curative properties towards type II diabetes, prediabetes and their associated acute or chronic complicationsSECTION 8 - CANCELLED—
009Electronic databases and computer programs for retrieving, compiling, integrating and sending data relating to research on type II diabetes, prediabetes and their associated acute or chronic complications in particular experimental data concerning the targets, biomarkers, cellular models and animal testing models which are being used or developed; Electronic databases and computer programs for retrieving, compiling, integrating and sending data relating to methods for the preventive or curative treatment of type II diabetes, of prediabetes and their acute or chronic complications; Electronic databases and computer programs for retrieving, compiling, integrating and sending medical data relating to the condition of patients monitored for the preventive or curative treatment of type II diabetes, of prediabetes and their acute or chronic complicationsSECTION 8 - CANCELLED—
042Scientific research in the field of prevention, diagnosis, screening, preventive or curative treatment of type II diabetes, of prediabetes and their acute or chronic complications; Scientific research, in particular clinical research on the assessment of the effects of drugs and their compounds having preventive or curative properties of type II diabetes, prediabetes and their acute or chronic complications; Development and validation of tests for the diagnosis and medical follow-up of patients at risk or of patients suffering from type II diabetes, prediabetes and their associated acute or chronic complications; Development and validation of biological tests in vitro, ex vivo and in vivo for sorting and selecting compounds, products and substances intended for the preventive or curative treatment of type II diabetes, prediabetes and their associated acute or chronic complicationsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 9, 2024C8..CANCELLED SEC. 8 (6-YR)—
Feb 27, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Feb 27, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 12, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 12, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 22, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 31, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 21, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 20, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 20, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 25, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 25, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 25, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 25, 2017DOCKASSIGNED TO EXAMINER—
Feb 2, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 2, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance